JP2014533728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533728A5 JP2014533728A5 JP2014543517A JP2014543517A JP2014533728A5 JP 2014533728 A5 JP2014533728 A5 JP 2014533728A5 JP 2014543517 A JP2014543517 A JP 2014543517A JP 2014543517 A JP2014543517 A JP 2014543517A JP 2014533728 A5 JP2014533728 A5 JP 2014533728A5
- Authority
- JP
- Japan
- Prior art keywords
- patent document
- international publication
- protein kinase
- cancer
- atypical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010050991 protein kinase C zeta Proteins 0.000 description 7
- 102100019666 PRKCZ Human genes 0.000 description 6
- 101710038827 PRKCI Proteins 0.000 description 5
- 102100019670 PRKCI Human genes 0.000 description 5
- 210000004027 cells Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 101710038724 F2RL3 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102100014639 PAWR Human genes 0.000 description 2
- 101700032631 PAWR Proteins 0.000 description 2
- 102000001253 Protein Kinases Human genes 0.000 description 2
- 108060006633 Protein Kinases Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229960001603 Tamoxifen Drugs 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- 102100016662 ERBB2 Human genes 0.000 description 1
- 208000007276 Esophageal Squamous Cell Carcinoma Diseases 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 108010027279 Facilitative Glucose Transport Proteins Proteins 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 102100011189 NCOA3 Human genes 0.000 description 1
- 101700068083 NCOA3 Proteins 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 101700047390 PKD1 Proteins 0.000 description 1
- 230000025458 RNA interference Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 101700063227 aPKC Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003034 chemosensitisation Effects 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 230000004736 colon carcinogenesis Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 101710038852 pkc-3 Proteins 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
Description
医薬品として使用するためのaPKC阻害剤に対する必要性が存在する。
この出願の発明に関連する先行技術文献情報としては、以下のものがある(国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む)。
(先行技術文献)
(特許文献)
(特許文献1) 米国特許第4,196,207号明細書
(特許文献2) 米国特許出願公開第2002/0151544号明細書
(特許文献3) 米国特許出願公開第2005/0153989号明細書
(特許文献4) 米国特許出願公開第2007/0010402号明細書
(特許文献5) カナダ国特許出願公開第2423981号明細書
(特許文献6) 特開2000−38350号公報
(特許文献7) 国際公開第1999/40091号
(特許文献8) 国際公開第2000/61586号
(特許文献9) 国際公開第2001/23389号
(特許文献10) 国際公開第2001/83456号
(特許文献11) 国際公開第2003/022214号
(特許文献12) 国際公開第2003/049739号
(特許文献13) 国際公開第2004/017950号
(特許文献14) 国際公開第2004/029060号
(特許文献15) 国際公開第2004/065391号
(特許文献16) 国際公開第2004/111057号
(特許文献17) 国際公開第2005/067546号
(特許文献18) 国際公開第2005/123087号
(特許文献19) 国際公開第2006/010568号
(特許文献20) 国際公開第2006/093518号
(特許文献21) 国際公開第2006/100095号
(特許文献22) 国際公開第2007/127175号
(特許文献23) 国際公開第2008/037607号
(特許文献24) 国際公開第2008/073785号
(特許文献25) 国際公開第2009/144584号
(特許文献26) 国際公開第2010/080996号
(特許文献27) 国際公開第2011/051452号
(特許文献28) 国際公開第2011/130628号
(非特許文献)
(非特許文献1) BALENDRAN et al.,"A 3−Phosphoinositide−dependent Protein Kinase−1(PDK1)Docking Site Is Required for the Phosphorylation of Protein Kinase Cζ(PKCζ)and PKC−related Kinase 2 by PDKl,"J. Bioi.Chem.(2000)275,pp 20806−20813
(非特許文献2) BERGE et al.,"Pharmaceutical Salts,"J.Pharm.Sci.(1977)66,pp 1−19
(非特許文献3) EDER et al.,"Atypical PKC contributes to poor prognosis through loss of apical−basal polarity and Cyclin E overexpression in ovarian cancer,"Proc.Natl Acad.Sci.(2005)102,PP 12519−12524
(非特許文献4) FARESE et al.,"Muscle−specific knockout of PKC−λ impairs glucose transport and induces metabolic and diabetic syndromes,"J.Clin.Invest.(2007) 117,pp 2289−2301
(非特許文献5) FIELDS et al.,"Protein kinase Cl: Human oncogene,prognostic marker and therapeutic target,"Pharmacol.Res.(2007)55,pp 487−497
(非特許文献6) FILOMENKO et al.,"Atypical Protein Kinase Cζ as a Target for Chemosensitization of Tumor Cells,"Cancer Res.(2002)62;pp 1815−1821
(非特許文献7) GARCIA−CAO et al.,"Tumour−suppression activity of the proapoptotic regulator Par4,"EMBO Reports(2005)6,pp 577−583
(非特許文献8) INOUE et al.,"Requirement of Androgen−Dependent Activation of Protein Kinase Cζ for Androgen−Dependent Cell Proliferation in LNCaP Cells and Its Roles in Transition to Androgen−Independent Cells,"Mol.Endocrinology(2006)20;pp 3053−3069
(非特許文献9) IORNS et al.,"Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization,"Biochem.J.(2009)417,pp 361−370
(非特許文献10) JOSHI et al.,"Par−4 inhibits Ak5 and suppresses Ras−induced lung tumorigenesis,"EMBO Journal(2008)27,pp 2181−2193
(非特許文献11) KOJIMA et al.,"The overexpression and altered localization of the atypical protein kinase Cλ/ι in breast cancer correlates with the pathologic type of these tumors,"Human Pathology(2008)39,pp 824−831
(非特許文献12) LEITGES et al.,"Targeted Disruption of the ζPKC Gene Results in the Impairment of the NF−KB Pathway,"Mol.Cell(2001)8,pp 771−780
(非特許文献13) LESEUX et al.,"PKCζ−mTOR pathway: a new target for rituximab therapy in follicular lymphoma,"Blood(2008)111,pp 285−291
(非特許文献14) MURRAY et al.,"Protein kinase Cι is required for Ras transformation and colon carcinogenesis in vivo,"J.Cell Biology(2004)164,pp 797−802
(非特許文献15) ONO et al.,"Protein Kinase Cζ subspecies from rat brain: Its structure,expression,and properties,"Proc.Natl.Acad.Sci.USA(1989)86,pp 3099−3103
(非特許文献16) OSBORNE et al.,"Role of the Estrogen Receptor Coactivator AIBI(SRC−3)and HER−2/neu in Tamoxifen Resistance in Breast Cancer,"J.Natl.Cancer Inst.(2003)95,PP 353−61
(非特許文献17) PLO et al.,"Overexpression of the Atypical Protein Kinase Cζ Reduces Topoisomerase II Catalytic Activity,Cleavable Complexes Formation and Drug−induced Cytotoxicity in Monocytic U937 Leukemia Cells,"J.Biological Chem.(2002)277,pp 31407−31415
(非特許文献18) REGALA et al.,"Atypical Protein Kinase Cι is an Oncogene in Human Non−Small Cell Lung Cancer,"Cancer Res.(2005)65; pp 8905−8911
(非特許文献19) REGALA et al.,"Atypical Protein Kinase Cι Expression and Aurothiomalate Sensitivity in Human Lung Cancer Cells,"Cancer Res.(2008)68,pp 5888−5895
(非特許文献20) REGALA et al.,"Atypical Protein Kinase Cι Plays a Critical Role in Human Lung Cancer Cell Growth and Tumorigenicity,"J.Bioloqical Chem.(2005)280,pp 31109−31115
(非特許文献21) SUZUKI et al.,"The PAR−aPKC system: lessons in polarity,"J.Cell Sci.(2006)119,pp 979−987
(非特許文献22) XIN et al.,"Protein Kinase Cζ Abrogates the Proapoptotic Function of Bax Through Phosphorylation,"J.Biological Chem.(2007)282,pp 21268−21277
(非特許文献23) YANG et al.,"Amplification of PRKCI,Located in 3q26,is Associated with Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma,"Genes,Chromosomes & Cancer(2008)47,pp 127−136
(非特許文献24) ZHANG et al.,"Integrative Genomic Analysis of Protein Kinase C(PKC)Family Identifies PKCι as a Biomarker and Potential Oncogene in Ovarian Carcinoma,"Cancer Res.(2006)66,pp 4627−4635
この出願の発明に関連する先行技術文献情報としては、以下のものがある(国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む)。
(先行技術文献)
(特許文献)
(特許文献1) 米国特許第4,196,207号明細書
(特許文献2) 米国特許出願公開第2002/0151544号明細書
(特許文献3) 米国特許出願公開第2005/0153989号明細書
(特許文献4) 米国特許出願公開第2007/0010402号明細書
(特許文献5) カナダ国特許出願公開第2423981号明細書
(特許文献6) 特開2000−38350号公報
(特許文献7) 国際公開第1999/40091号
(特許文献8) 国際公開第2000/61586号
(特許文献9) 国際公開第2001/23389号
(特許文献10) 国際公開第2001/83456号
(特許文献11) 国際公開第2003/022214号
(特許文献12) 国際公開第2003/049739号
(特許文献13) 国際公開第2004/017950号
(特許文献14) 国際公開第2004/029060号
(特許文献15) 国際公開第2004/065391号
(特許文献16) 国際公開第2004/111057号
(特許文献17) 国際公開第2005/067546号
(特許文献18) 国際公開第2005/123087号
(特許文献19) 国際公開第2006/010568号
(特許文献20) 国際公開第2006/093518号
(特許文献21) 国際公開第2006/100095号
(特許文献22) 国際公開第2007/127175号
(特許文献23) 国際公開第2008/037607号
(特許文献24) 国際公開第2008/073785号
(特許文献25) 国際公開第2009/144584号
(特許文献26) 国際公開第2010/080996号
(特許文献27) 国際公開第2011/051452号
(特許文献28) 国際公開第2011/130628号
(非特許文献)
(非特許文献1) BALENDRAN et al.,"A 3−Phosphoinositide−dependent Protein Kinase−1(PDK1)Docking Site Is Required for the Phosphorylation of Protein Kinase Cζ(PKCζ)and PKC−related Kinase 2 by PDKl,"J. Bioi.Chem.(2000)275,pp 20806−20813
(非特許文献2) BERGE et al.,"Pharmaceutical Salts,"J.Pharm.Sci.(1977)66,pp 1−19
(非特許文献3) EDER et al.,"Atypical PKC contributes to poor prognosis through loss of apical−basal polarity and Cyclin E overexpression in ovarian cancer,"Proc.Natl Acad.Sci.(2005)102,PP 12519−12524
(非特許文献4) FARESE et al.,"Muscle−specific knockout of PKC−λ impairs glucose transport and induces metabolic and diabetic syndromes,"J.Clin.Invest.(2007) 117,pp 2289−2301
(非特許文献5) FIELDS et al.,"Protein kinase Cl: Human oncogene,prognostic marker and therapeutic target,"Pharmacol.Res.(2007)55,pp 487−497
(非特許文献6) FILOMENKO et al.,"Atypical Protein Kinase Cζ as a Target for Chemosensitization of Tumor Cells,"Cancer Res.(2002)62;pp 1815−1821
(非特許文献7) GARCIA−CAO et al.,"Tumour−suppression activity of the proapoptotic regulator Par4,"EMBO Reports(2005)6,pp 577−583
(非特許文献8) INOUE et al.,"Requirement of Androgen−Dependent Activation of Protein Kinase Cζ for Androgen−Dependent Cell Proliferation in LNCaP Cells and Its Roles in Transition to Androgen−Independent Cells,"Mol.Endocrinology(2006)20;pp 3053−3069
(非特許文献9) IORNS et al.,"Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization,"Biochem.J.(2009)417,pp 361−370
(非特許文献10) JOSHI et al.,"Par−4 inhibits Ak5 and suppresses Ras−induced lung tumorigenesis,"EMBO Journal(2008)27,pp 2181−2193
(非特許文献11) KOJIMA et al.,"The overexpression and altered localization of the atypical protein kinase Cλ/ι in breast cancer correlates with the pathologic type of these tumors,"Human Pathology(2008)39,pp 824−831
(非特許文献12) LEITGES et al.,"Targeted Disruption of the ζPKC Gene Results in the Impairment of the NF−KB Pathway,"Mol.Cell(2001)8,pp 771−780
(非特許文献13) LESEUX et al.,"PKCζ−mTOR pathway: a new target for rituximab therapy in follicular lymphoma,"Blood(2008)111,pp 285−291
(非特許文献14) MURRAY et al.,"Protein kinase Cι is required for Ras transformation and colon carcinogenesis in vivo,"J.Cell Biology(2004)164,pp 797−802
(非特許文献15) ONO et al.,"Protein Kinase Cζ subspecies from rat brain: Its structure,expression,and properties,"Proc.Natl.Acad.Sci.USA(1989)86,pp 3099−3103
(非特許文献16) OSBORNE et al.,"Role of the Estrogen Receptor Coactivator AIBI(SRC−3)and HER−2/neu in Tamoxifen Resistance in Breast Cancer,"J.Natl.Cancer Inst.(2003)95,PP 353−61
(非特許文献17) PLO et al.,"Overexpression of the Atypical Protein Kinase Cζ Reduces Topoisomerase II Catalytic Activity,Cleavable Complexes Formation and Drug−induced Cytotoxicity in Monocytic U937 Leukemia Cells,"J.Biological Chem.(2002)277,pp 31407−31415
(非特許文献18) REGALA et al.,"Atypical Protein Kinase Cι is an Oncogene in Human Non−Small Cell Lung Cancer,"Cancer Res.(2005)65; pp 8905−8911
(非特許文献19) REGALA et al.,"Atypical Protein Kinase Cι Expression and Aurothiomalate Sensitivity in Human Lung Cancer Cells,"Cancer Res.(2008)68,pp 5888−5895
(非特許文献20) REGALA et al.,"Atypical Protein Kinase Cι Plays a Critical Role in Human Lung Cancer Cell Growth and Tumorigenicity,"J.Bioloqical Chem.(2005)280,pp 31109−31115
(非特許文献21) SUZUKI et al.,"The PAR−aPKC system: lessons in polarity,"J.Cell Sci.(2006)119,pp 979−987
(非特許文献22) XIN et al.,"Protein Kinase Cζ Abrogates the Proapoptotic Function of Bax Through Phosphorylation,"J.Biological Chem.(2007)282,pp 21268−21277
(非特許文献23) YANG et al.,"Amplification of PRKCI,Located in 3q26,is Associated with Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma,"Genes,Chromosomes & Cancer(2008)47,pp 127−136
(非特許文献24) ZHANG et al.,"Integrative Genomic Analysis of Protein Kinase C(PKC)Family Identifies PKCι as a Biomarker and Potential Oncogene in Ovarian Carcinoma,"Cancer Res.(2006)66,pp 4627−4635
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161563310P | 2011-11-23 | 2011-11-23 | |
US61/563,310 | 2011-11-23 | ||
PCT/US2012/065831 WO2013078126A1 (en) | 2011-11-23 | 2012-11-19 | Thienopyrimidine inhibitors of atypical protein kinase c |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014533728A JP2014533728A (ja) | 2014-12-15 |
JP2014533728A5 true JP2014533728A5 (ja) | 2016-01-14 |
JP6206926B2 JP6206926B2 (ja) | 2017-10-04 |
Family
ID=47295200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014543517A Active JP6206926B2 (ja) | 2011-11-23 | 2012-11-19 | 異常なプロテインキナーゼcのチエノピリミジン阻害剤 |
Country Status (12)
Country | Link |
---|---|
US (3) | US9604994B2 (ja) |
EP (2) | EP2782917B1 (ja) |
JP (1) | JP6206926B2 (ja) |
CN (1) | CN104053661B (ja) |
AU (2) | AU2012340869B2 (ja) |
CA (1) | CA2855446C (ja) |
ES (1) | ES2575143T3 (ja) |
HK (1) | HK1202529A1 (ja) |
IL (1) | IL232559B (ja) |
IN (1) | IN2014CN04558A (ja) |
MX (1) | MX355088B (ja) |
WO (1) | WO2013078126A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012097013A1 (en) | 2011-01-10 | 2012-07-19 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
TWI589579B (zh) * | 2012-01-10 | 2017-07-01 | 林伯士艾瑞斯公司 | Irak抑制劑及其用途 |
WO2014011902A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
US9067948B2 (en) | 2012-07-11 | 2015-06-30 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
CA2890911A1 (en) | 2013-01-10 | 2014-07-17 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2015048281A1 (en) | 2013-09-27 | 2015-04-02 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
TWI675836B (zh) * | 2014-03-25 | 2019-11-01 | 美商伊格尼塔公司 | 非典型蛋白質激酶c之氮雜喹唑啉抑制劑 |
JP7114076B2 (ja) | 2015-12-22 | 2022-08-08 | シャイ・セラピューティクス・エルエルシー | がん及び炎症性疾患の処置のための化合物 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
KR20180075228A (ko) * | 2016-12-26 | 2018-07-04 | 한미약품 주식회사 | 싸이에노피리미딘 화합물의 신규 제조방법 및 중간체 |
MX2019014875A (es) | 2017-06-21 | 2021-01-29 | SHY Therapeutics LLC | Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica. |
WO2019119206A1 (en) | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
CN108658999B (zh) * | 2018-04-24 | 2021-02-05 | 温州大学 | 2-苯基杂环并[2,3-d]嘧啶-4(3H)-酮类化合物的合成方法 |
EP3632908A1 (en) | 2018-10-02 | 2020-04-08 | Inventiva | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
MX2021005875A (es) * | 2018-11-20 | 2021-09-23 | Univ Georgetown | Composiciones y métodos para el tratamiento de trastornos neurodegenerativos, miodegenerativos y de almacenamiento lisosómico. |
EP3725788A1 (en) * | 2019-04-15 | 2020-10-21 | Bayer AG | Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides |
CN116410205A (zh) * | 2021-12-29 | 2023-07-11 | 上海皓元生物医药科技有限公司 | 一种3-取代-9-甲基-噻吩并三唑并噁嗪类化合物的制备方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196207A (en) | 1977-05-23 | 1980-04-01 | Ici Australia Limited | Process for controlling eradicating or preventing infestations of animals by Ixodid ticks |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
JP2000038350A (ja) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | 糖尿病治療薬 |
TW564247B (en) | 1999-04-08 | 2003-12-01 | Akzo Nobel Nv | Bicyclic heteraromatic compound |
US6506762B1 (en) | 1999-09-30 | 2003-01-14 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
CN100345830C (zh) | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
KR20030034232A (ko) | 2000-09-29 | 2003-05-01 | 닛뽕소다 가부시키가이샤 | 티에노피리미딘 화합물 및 그 염 및 제조방법 |
WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
EP1474147B1 (en) | 2001-12-07 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Pyrimidine-based compounds useful as gsk-3 inhibitors |
WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
AR044743A1 (es) | 2002-09-26 | 2005-10-05 | Nihon Nohyaku Co Ltd | Herbicida, metodo de emplearlo, derivados de tienopirimidina sustituida,compuestos intermediarios, y procedimientos que se utilizan para producirlos, |
ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
ES2324536T7 (es) | 2003-06-11 | 2012-03-16 | Xention Limited | Derivados de tenopirimidina como inhibidores de los canales de potasio. |
WO2005069865A2 (en) | 2004-01-13 | 2005-08-04 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
WO2005123087A2 (en) | 2004-06-15 | 2005-12-29 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
WO2006093518A2 (en) | 2004-06-25 | 2006-09-08 | Apath, Llc | Thienyl compounds for treating virus-related conditions |
WO2006010568A2 (de) | 2004-07-23 | 2006-02-02 | Curacyte Discovery Gmbh | Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung |
DE102005013621A1 (de) | 2005-03-24 | 2006-09-28 | Curacyte Discovery Gmbh | Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika |
EP2041139B1 (en) | 2006-04-26 | 2011-11-09 | F. Hoffmann-La Roche AG | Pharmaceutical compounds |
WO2008037607A1 (de) | 2006-09-25 | 2008-04-03 | Basf Se | Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen |
RU2470936C2 (ru) * | 2006-12-07 | 2012-12-27 | Дженентек, Инк. | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения |
JP2011521941A (ja) | 2008-05-30 | 2011-07-28 | ミトロジクス | Ant−リガンド分子および生物学的アプリケ−ション |
KR101430424B1 (ko) * | 2009-01-08 | 2014-08-14 | 쿠리스 인코퍼레이션 | 아연 결합 모이어티를 갖는 포스포이노시티드 3-키나제 억제제 |
KR101675614B1 (ko) | 2009-10-29 | 2016-11-11 | 벡투라 리미티드 | Jak3 키나아제 저해제로서의 n―함유 헤테로아릴 유도체 |
JP2013525308A (ja) * | 2010-04-16 | 2013-06-20 | キュリス,インコーポレイテッド | K−ras変異を有する癌の治療 |
-
2012
- 2012-11-19 AU AU2012340869A patent/AU2012340869B2/en active Active
- 2012-11-19 EP EP12795969.0A patent/EP2782917B1/en active Active
- 2012-11-19 ES ES12795969.0T patent/ES2575143T3/es active Active
- 2012-11-19 MX MX2014006233A patent/MX355088B/es active IP Right Grant
- 2012-11-19 IN IN4558CHN2014 patent/IN2014CN04558A/en unknown
- 2012-11-19 CA CA2855446A patent/CA2855446C/en active Active
- 2012-11-19 CN CN201280057805.9A patent/CN104053661B/zh active Active
- 2012-11-19 JP JP2014543517A patent/JP6206926B2/ja active Active
- 2012-11-19 WO PCT/US2012/065831 patent/WO2013078126A1/en active Application Filing
- 2012-11-19 EP EP15196784.1A patent/EP3048106B1/en active Active
-
2014
- 2014-05-12 IL IL232559A patent/IL232559B/en active IP Right Grant
- 2014-05-22 US US14/285,007 patent/US9604994B2/en active Active
-
2015
- 2015-03-20 HK HK15102864.2A patent/HK1202529A1/zh unknown
-
2017
- 2017-01-26 US US15/417,191 patent/US10183950B2/en active Active
- 2017-06-02 AU AU2017203725A patent/AU2017203725B2/en active Active
-
2018
- 2018-12-06 US US16/212,582 patent/US10954251B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014533728A5 (ja) | ||
Du et al. | Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity | |
Lu et al. | Potential clinical application of lncRNAs in non-small cell lung cancer | |
Zeng et al. | AFAP1-AS1, a long noncoding RNA upregulated in lung cancer and promotes invasion and metastasis | |
Zhang et al. | Increased expression of long noncoding RNA TUG1 predicts a poor prognosis of gastric cancer and regulates cell proliferation by epigenetically silencing of p57 | |
Li et al. | Id-1 activation of PI3K/Akt/NFκB signaling pathway and its significance in promoting survival of esophageal cancer cells | |
Liu et al. | Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression | |
Xie et al. | Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma | |
Li et al. | Long non-coding RNA HOXD-AS1 in cancer | |
Liu et al. | miR-200b as a prognostic factor targets multiple members of RAB family in glioma | |
Ma et al. | lncRNA GCAWKR promotes gastric cancer development by scaffolding the chromatin modification factors WDR5 and KAT2A | |
Santasusagna et al. | miR-328 mediates a metabolic shift in colon cancer cells by targeting SLC2A1/GLUT1 | |
Deng et al. | The lncRNA-MYC regulatory network in cancer | |
Zhang et al. | RBP EIF2S2 promotes tumorigenesis and progression by regulating MYC-mediated inhibition via FHIT-related enhancers | |
Kim et al. | MicroRNA-mediated regulation of KRAS in cancer | |
Wang et al. | Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targets | |
Zhou et al. | microRNA-365-targeted nuclear factor I/B transcriptionally represses cyclin-dependent kinase 6 and 4 to inhibit the progression of cutaneous squamous cell carcinoma | |
Hamurcu et al. | FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer | |
Nema et al. | Emerging role of sphingosine-1-phosphate signaling in head and neck squamous cell carcinoma | |
Li et al. | CREB1 contributes colorectal cancer cell plasticity by regulating lncRNA CCAT1 and NF-κB pathways | |
Wei et al. | miR-223-RhoB signaling pathway regulates the proliferation and apoptosis of colon adenocarcinoma | |
Gu et al. | LINC01224 promotes colorectal cancer progression through targeting miR-485-5p/MYO6 axis | |
Tan et al. | Inhibition of Vav3 could reverse the drug resistance of gastric cancer cells by downregulating JNK signaling pathway | |
Chen et al. | Circular RNA circ_0001368 inhibited growth and invasion in renal cell carcinoma by sponging miR-492 and targeting LATS2 | |
Shuai et al. | lncRNA TRMP-S directs dual mechanisms to regulate p27-mediated cellular senescence |